Who
Ramtin Agah
Chief Medical Officer
Company insider
Files Form 4 as: Chief Medical Officer, RenovoRx.
In numbers
- Trades disclosed
- 33
- Buys
- 14
- Sells
- 0
- Bought
- $190K
- Sold
- $0
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 30 Aug 2021
- Last trade
- 3 Apr 2026
- Last filed
- 7 Apr 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 3 Apr 2026filed 7 Apr 2026 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —621,727 at $0.00 | filing |
| 3 Apr 2026filed 7 Apr 2026 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —621,727 at $0.00 | filing |
| 21 Jan 2026filed 22 Jan 2026 | RNXT RenovoRxBiotechnology | SEC FORM 4 Bought | $9,97510,000 at $0.9975 | filing |
| 21 Jan 2026filed 22 Jan 2026 | RNXT RenovoRxBiotechnology | SEC FORM 4 Bought | $10K10,000 at $1.00 | filing |
| 31 Dec 2025filed 5 Jan 2026 | RNXT RenovoRxBiotechnology | SEC FORM 4 Bought | $8,4249,795 at $0.86 | filing |
| 31 Dec 2025filed 5 Jan 2026 | RNXT RenovoRxBiotechnology | SEC FORM 4 Bought | $8,4249,795 at $0.86 | filing |
| 30 Dec 2025filed 2 Jan 2026 | RNXT RenovoRxBiotechnology | SEC FORM 4 Bought | $169205 at $0.826 | filing |
| 30 Dec 2025filed 2 Jan 2026 | RNXT RenovoRxBiotechnology | SEC FORM 4 Bought | $170205 at $0.83 | filing |
| 16 Dec 2025filed 17 Dec 2025 | RNXT RenovoRxBiotechnology | SEC FORM 4 Bought | $10K12,000 at $0.85 | filing |
| 5 Dec 2025filed 8 Dec 2025 | RNXT RenovoRxBiotechnology | SEC FORM 4 Bought | $9,60010,000 at $0.96 | filing |
| 24 Nov 2025filed 24 Nov 2025 | RNXT RenovoRxBiotechnology | SEC FORM 4 Bought | $9,60012,000 at $0.80 | filing |
| 21 Nov 2025filed 24 Nov 2025 | RNXT RenovoRxBiotechnology | SEC FORM 4 Bought | $8,00010,000 at $0.80 | filing |
| 1 Jul 2025filed 3 Jul 2025 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —63,636 at $0.00 | filing |
| 5 Jun 2025filed 9 Jun 2025 | RNXT RenovoRxBiotechnology | SEC FORM 4 Bought | $29K21,000 at $1.40 | filing |
| 22 Apr 2025filed 6 Jun 2025 | RNXT RenovoRxBiotechnology | SEC FORM 4 Code G | —400,000 at $0.00 | filing |
| 15 Apr 2025filed 17 Apr 2025 | RNXT RenovoRxBiotechnology | SEC FORM 4 Bought | $14K15,000 at $0.90 | filing |
| 14 Apr 2025filed 16 Apr 2025 | RNXT RenovoRxoption or derivative · Biotechnology | SEC FORM 4 Code A | —254,542 at $0.00 | filing |
| 11 Apr 2025filed 14 Apr 2025 | RNXT RenovoRxBiotechnology | SEC FORM 4 Bought | $16K20,000 at $0.80 | filing |
| 9 Apr 2025filed 10 Apr 2025 | RNXT RenovoRxBiotechnology | SEC FORM 4 Bought | $24K30,000 at $0.81 | filing |
| 8 Apr 2025filed 9 Apr 2025 | RNXT RenovoRxBiotechnology | SEC FORM 4 Bought | $22K26,000 at $0.84 | filing |
News
RenovoRx Advances TAMP™ into Borderline Resectable Pancreatic Cancer with First Patient Enrolled in Investigator-Initiated PRISM-TAMP TrialRNXT · manilatimes.net · 7 Oct 2026
0 headlines in the last 90 days name Ramtin Agah; 1 article from the last 14 days about the 1 company they traded most, at most three about any one of them.